Author

Valérie Cuvier

Observed names: Cuvier, Valerie, V. Cuvier, Valerie Cuvier

Institution: Inotrem (France)

Observed institution: Inotrem (France)

OpenAlex ID: A5077637262

Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results

2014 · D. Atar, H. Arheden, et al. · European Heart Journal · 197

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

2014 · T. Lenglet, L. Lacomblez, et al. · European Journal of Neurology · 136

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

2023 · Bruno François, Simon Lambden, et al. · The Lancet Respiratory Medicine · 88

Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

2020 · Bruno François, Xavier Wittebole, et al. · Intensive Care Medicine · 73

A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition

2018 · Valerie Cuvier, Ulrike Lorch, et al. · British Journal of Clinical Pharmacology · 45

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

2021 · Bruno Francois, Simon Lambden, et al. · BMJ Open · 21

Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial

2023 · Bruno François, Simon Lambden, et al. · EClinicalMedicine · 17

Results of a Phase 1b study to confirm safety and tolerability of olesoxime in multiple sclerosis patients (P7.282)

2015 · Jean Pelletier, Jean-Philippe Ranjeva, et al. · Neurology · 9

Results of a Phase II Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3- to 25-Year-Old Spinal Muscular Atrophy Patients

2014 · J. Kirschner, E. Dessaud, et al. · Neuropediatrics · 9

2014 · E. Dessaud, C. André, et al. · Neuromuscular Disorders · 5

Identification of the biomarker soluble TREM-1 as a candidate for a personalised medicine approach for nangibotide treatment of septic shock

2022 · Simon Lambden, Jean-Marie Grouin, et al. · Research Square · 1

Sepsis 2016 Paris : Paris, France. 6-8 December 2016

2016 · Marcia Ingles, Gary Crowfoot, et al. · Europe PMC (PubMed Central)

Sepsis 2016 Paris

2016 · Marcia Ingles, Gary Crowfoot, et al. · Critical Care

Works count: 14

Citation count: 602

H-index: 9

I10-index: 7